Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. Among authors: konecny ge. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, Martin L, Matei D, Miller DS, Robertson S, Barroilhet L, Uppal S, Hendrickson AW, Gershenson DM, Gray HJ, Hakam A, Jain A, Konecny GE, Moroney J, Ratner E, Schorge J, Thaker PH, Werner TL, Zsiros E, Behbakht K, Chen LM, DeRosa M, Eisenhauer EL, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez RD, Armstrong DK. Liu J, et al. Among authors: konecny ge. J Natl Compr Canc Netw. 2024 Oct;22(8):512-519. doi: 10.6004/jnccn.2024.0052. J Natl Compr Canc Netw. 2024. PMID: 39413835
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P, Method M, Wang Y, Coleman RL, Birrer M, Matulonis UA. Moore KN, et al. Among authors: konecny ge. Gynecol Oncol. 2024 Dec;191:249-258. doi: 10.1016/j.ygyno.2024.10.013. Epub 2024 Oct 25. Gynecol Oncol. 2024. PMID: 39461270
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. J Clin Oncol. 2024 Nov 26:JCO2401326. doi: 10.1200/JCO-24-01326. Online ahead of print. J Clin Oncol. 2024. PMID: 39591551
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial.
Alvarez Secord A, Lewin SN, Murphy CG, Cecere SC, Barquín A, Gálvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Rubio Pérez MJ, Bonaventura A, Diver EJ, Ayuk SM, Wang Y, Corr BR, Salutari V. Alvarez Secord A, et al. Among authors: konecny ge. Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. doi: 10.1016/j.annonc.2024.11.011. Online ahead of print. Ann Oncol. 2024. PMID: 39617145
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
Cristea MC, Stewart D, Synold T, Ruel N, Mortimer J, Wang E, Jung A, Wilczynski S, Konecny GE, Eng M, Kilpatrick L, Han E, Dellinger T, Hakim A, Lee S, Morgan RJ, Wakabayashi MT, Frankel PH. Cristea MC, et al. Among authors: konecny ge. Gynecol Oncol. 2024 Mar;182:124-131. doi: 10.1016/j.ygyno.2023.12.017. Epub 2024 Jan 22. Gynecol Oncol. 2024. PMID: 38262235 Clinical Trial.
ZNFX1 functions as a master regulator of epigenetically induced pathogen mimicry and inflammasome signaling in cancer.
Stojanovic L, Abbotts R, Tripathi K, Coon CM, Rajendran S, Abbasi Farid E, Hostetter G, Guarnieri JW, Wallace DC, Liu S, Wan J, Calendo G, Marker R, Gohari Z, Inayatullah MMA, Tiwari VK, Kader T, Santagata S, Drapkin R, Kommoss S, Pfisterer J, Konecny GE, Coopergard R, Issa JJ, Winterhoff BJN, Topper MJ, Sandusky GE, Miller KD, Baylin SB, Nephew KP, Rassool FV. Stojanovic L, et al. Among authors: konecny ge. Cancer Res. 2025 Jan 13. doi: 10.1158/0008-5472.CAN-24-1286. Online ahead of print. Cancer Res. 2025. PMID: 39804147
115 results